Contact Information

Call us at: (614) 722-2859

Institute for Genomic Medicine575 Children’s CrossroadColumbus, OH 43215 (map)

Learn more about Yassmine MN Akkari

Biography

Yassmine Akkari, PhD, is a senior director within the Institute for Genomic Medicine at Nationwide Children’s Hospital. She is triple certified by the American Board of Medical Genetics and Genomics in the specialties of Clinical Cytogenetics, Clinical Molecular Genetics and PhD Medical Genetics. She earned her Bachelor of Sciences degree in Biology from the American University of Beirut and her PhD in Molecular Genetics at The Ohio State University. Following her postdoctoral research and clinical training at the Oregon Health & Sciences University (OHSU), she joined Legacy Health (LH) in Portland, Oregon as the Scientific director of Cytogenetics and Molecular Pathology. During her tenure at LH, she contributed to the successful validation of cytogenetic testing for both germline and somatic specimens, pan-cancer solid tumor next generation sequencing gene panels, and infectious disease, and directed all aspects of clinical genetics operations and workflow. In addition, she provided genetic counseling services for patients with complex genomic results in both the pediatric and prenatal clinics. She also participated in the successful accreditation of the Cytogenetics and Molecular Pathology laboratories at LH to the ISO 15189 standard focusing on the continuum of care directly connected with improved patient safety, risk mitigation and operational efficiency. Dr. Akkari has served as the President of the Cancer Genomics Consortium (CGC), the Vice Chair of the CAP/ACMG Cytogenetics resource Committee, and the Chair of the Association of Molecular Pathology (AMP) Training and Education Committee. Currently, she is an Expert Member of the WHO Blue Books for hematopoietic and lymphoid tissues and genetic tumor syndromes, the Chair-elect of AMP’s Program Committee, and is a member of the Children’s Oncology Group Cytogenetics Committee and the ACMG Laboratory Quality Assurance Committee. She is interested in all aspects of genomics as it pertains to disease diagnostics and therapy. This includes test development and clinical validations particularly in the setting of pediatric hematologic disease, CNS tumors and genetic predisposition syndromes.

Awards, Honors & Organizations

Expert Member for Genetic Tumor Syndromes, WHO-IARC, 2022 - Present Expert Member for Hematologic Malignancies, WHO-IARC, 2021 - Present Member, ClinGen Pediatric Cancer Taskforce, 2021 - Present Editorial Board, Head and Neck Pathology, 2021 - Present Board of Directors, Program Chair-Elect, Association for Molecular Pathologists, 2021 - 2023 Member, ACMG Laboratory Quality Assurance Committee, 2020 - Present Past-President, Cancer Genomics Consortium (CGC), 2020 - 2021 Vice Chair, CAP/ACMG Training and Education Committee, 2019 - 2021 Member, Children’s Oncology Group (COG) Cytogenetics Steering Committee, 2018 - Present Editorial Advisor, Medical Lab Management, 2018 - Present Vice Chair, CAP/ACMG Cytogenetics Committee, 2018 - 2021 Member, CAP/ACMG Cytogenetics Committee, 2013 - 2018 Fellow, American College of Medical Genetics and Genomics, 2005 - Present

Research

Publications

                  Koleilat A, Smadbeck JB, Zepeda-Mendoza CJ, Williamson CM, Pitel BA, Golden CL, Xu X, Greipp PT, Ketterling RP, Hoppman NL, Peterson JF, Harrison CJ, Akkari YMN, Tsuchiya KD, Shago M, Baughn LB. Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children's Oncology Group. Genes Chromosomes Cancer. 2022 Dec; 61: 710-719.

                


                  Dungan JS, Klugman S, Darilek S, Malinowski J, Akkari YMN, Monaghan KG, Erwin A, Best RG, ACMG Board of Directors. Electronic address: documents@acmg.net. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2022 Dec 13;  

                


                  Levy B, Baughn LB, Akkari YMN, Chartrand S, LaBarge B, Claxton DF, Lennon PA, Cujar C, Kolhe R, Kroeger K, Pitel B, Sahajpal N, Sathanoori M, Vlad G, Zhang L, Fang M, Kanagal-Shamanna R, Broach JR. Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation. Blood Adv. 2022 Nov 23;  

                


                  Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 Sep; 24: 1991.

                


                  Gagnon MF, Smadbeck JB, Sharma N, Blackburn PR, Demasi Benevides J, Akkari YMN, Jaroscak JJ, Znoyko I, Wolff DJ, Schandl CA, Meyer R, Greipp PT, Xu X, Hoppman NL, Ketterling RP, Peterson JF, Baughn LB. Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL. Leuk Lymphoma. 2022 Sep; 63: 2243-2246.

                


                  Yang F, Akkari Y, Fan G, Olson S, Moore S. A novel heptasomy 21 associated with complete loss of heterozygosity and loss of function RUNX1 mutation in acute myeloid leukemia. Cancer Genet. 2022 Aug; 266-267: 69-73.

                


                  Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul; 36: 1703-1719.

                


                  Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 May; 24: 986-998.

                


                  Arcila ME, Snow AN, Akkari YMN, Chabot-Richards D, Pancholi P, Tafe LJ. Molecular Pathology Education: A Suggested Framework for Primary Care Resident Training in Genomic Medicine: A Report of the Association for Molecular Pathology Training and Education Committee. J Mol Diagn. 2022 May; 24: 430-441.

                


                  Akkari YMN, Baughn LB, Dubuc AM, Smith AC, Mallo M, Dal Cin P, Diez Campelo M, Gallego MS, Granada Font I, Haase DT, Schlegelberger B, Slavutsky I, Mecucci C, Levine RL, Hasserjian RP, Solé F, Levy B, Xu X. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood. 2022 Apr 14; 139: 2273-2284.

                


                  Wagner AH, Akkari Y, Li M, Roy A, Tsuchiya K, Raca G. Recommendations for future extensions to the HGNC gene fusion nomenclature. Leukemia. 2021 Dec; 35: 3611-3612.

                


                  Shao L, Akkari Y, Cooley LD, Miller DT, Seifert BA, Wolff DJ, Mikhail FM, ACMG Laboratory Quality Assurance Committee. Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021 Oct; 23: 1818-1829.

                


                  Larson DP, Akkari YM, Van Dyke DL, Raca G, Gardner JA, Rehder CW, Kaiser-Rogers KA, Eagle P, Yuhas JA, Gu J, Toydemir RM, Kearney H, Conlin LK, Tang G, Dolan MM, Ketterling RP, Peterson JF. Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee. Arch Pathol Lab Med. 2021 Feb 1; 145: 176-190.

                


                  Akkari YMN, Bruyere H, Hagelstrom RT, Kanagal-Shamanna R, Liu J, Luo M, Mikhail FM, Pitel BA, Raca G, Shago M, Shao L, Smith LR, Smolarek TA, Yenamandra A, Baughn LB. Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia. Cancer Genet. 2020 May; 243: 52-72.

                


                  Punj S, Akkari Y, Huang J, Yang F, Creason A, Pak C, Potter A, Dorschner MO, Nickerson DA, Robertson PD, Jarvik GP, Amendola LM, Schleit J, Simpson DK, Rope AF, Reiss J, Kauffman T, Gilmore MJ, Himes P, Wilfond B, Goddard KAB, Richards CS. Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory. Am J Hum Genet. 2018 Jun 7; 102: 1078-1089.

View More Publications

Education

Date of Appointment at Nationwide Children’s Hospital: 07/11/2022

Graduate School

The Ohio State University

Date Completed: 03/01/1997

Undergraduate School

American University of Beirut

Date Completed: 12/01/1989

Professional Experience

2022 - Present Nationwide Children’s Hospital, Senior Director, Institute for Genomic Medicine2007 - 2022 Legacy Health, Scientific Director, Cytogenetics and Molecular Pathology

Contact Information

Institute for Genomic Medicine

Call us at: (614) 722-2859

                    575 Children’s CrossroadColumbus, OH 43215 (map)

Connect with Yassmine MN Akkari

Connect on Twitter

Contact Information

Call us at: (614) 722-2859

Institute for Genomic Medicine575 Children’s CrossroadColumbus, OH 43215 (map)

Learn more about Yassmine MN Akkari

Biography

Yassmine Akkari, PhD, is a senior director within the Institute for Genomic Medicine at Nationwide Children’s Hospital. She is triple certified by the American Board of Medical Genetics and Genomics in the specialties of Clinical Cytogenetics, Clinical Molecular Genetics and PhD Medical Genetics. She earned her Bachelor of Sciences degree in Biology from the American University of Beirut and her PhD in Molecular Genetics at The Ohio State University. Following her postdoctoral research and clinical training at the Oregon Health & Sciences University (OHSU), she joined Legacy Health (LH) in Portland, Oregon as the Scientific director of Cytogenetics and Molecular Pathology. During her tenure at LH, she contributed to the successful validation of cytogenetic testing for both germline and somatic specimens, pan-cancer solid tumor next generation sequencing gene panels, and infectious disease, and directed all aspects of clinical genetics operations and workflow. In addition, she provided genetic counseling services for patients with complex genomic results in both the pediatric and prenatal clinics. She also participated in the successful accreditation of the Cytogenetics and Molecular Pathology laboratories at LH to the ISO 15189 standard focusing on the continuum of care directly connected with improved patient safety, risk mitigation and operational efficiency. Dr. Akkari has served as the President of the Cancer Genomics Consortium (CGC), the Vice Chair of the CAP/ACMG Cytogenetics resource Committee, and the Chair of the Association of Molecular Pathology (AMP) Training and Education Committee. Currently, she is an Expert Member of the WHO Blue Books for hematopoietic and lymphoid tissues and genetic tumor syndromes, the Chair-elect of AMP’s Program Committee, and is a member of the Children’s Oncology Group Cytogenetics Committee and the ACMG Laboratory Quality Assurance Committee. She is interested in all aspects of genomics as it pertains to disease diagnostics and therapy. This includes test development and clinical validations particularly in the setting of pediatric hematologic disease, CNS tumors and genetic predisposition syndromes.

Awards, Honors & Organizations

Expert Member for Genetic Tumor Syndromes, WHO-IARC, 2022 - Present Expert Member for Hematologic Malignancies, WHO-IARC, 2021 - Present Member, ClinGen Pediatric Cancer Taskforce, 2021 - Present Editorial Board, Head and Neck Pathology, 2021 - Present Board of Directors, Program Chair-Elect, Association for Molecular Pathologists, 2021 - 2023 Member, ACMG Laboratory Quality Assurance Committee, 2020 - Present Past-President, Cancer Genomics Consortium (CGC), 2020 - 2021 Vice Chair, CAP/ACMG Training and Education Committee, 2019 - 2021 Member, Children’s Oncology Group (COG) Cytogenetics Steering Committee, 2018 - Present Editorial Advisor, Medical Lab Management, 2018 - Present Vice Chair, CAP/ACMG Cytogenetics Committee, 2018 - 2021 Member, CAP/ACMG Cytogenetics Committee, 2013 - 2018 Fellow, American College of Medical Genetics and Genomics, 2005 - Present

Research

Publications

                  Koleilat A, Smadbeck JB, Zepeda-Mendoza CJ, Williamson CM, Pitel BA, Golden CL, Xu X, Greipp PT, Ketterling RP, Hoppman NL, Peterson JF, Harrison CJ, Akkari YMN, Tsuchiya KD, Shago M, Baughn LB. Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children's Oncology Group. Genes Chromosomes Cancer. 2022 Dec; 61: 710-719.

                


                  Dungan JS, Klugman S, Darilek S, Malinowski J, Akkari YMN, Monaghan KG, Erwin A, Best RG, ACMG Board of Directors. Electronic address: documents@acmg.net. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2022 Dec 13;  

                


                  Levy B, Baughn LB, Akkari YMN, Chartrand S, LaBarge B, Claxton DF, Lennon PA, Cujar C, Kolhe R, Kroeger K, Pitel B, Sahajpal N, Sathanoori M, Vlad G, Zhang L, Fang M, Kanagal-Shamanna R, Broach JR. Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation. Blood Adv. 2022 Nov 23;  

                


                  Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 Sep; 24: 1991.

                


                  Gagnon MF, Smadbeck JB, Sharma N, Blackburn PR, Demasi Benevides J, Akkari YMN, Jaroscak JJ, Znoyko I, Wolff DJ, Schandl CA, Meyer R, Greipp PT, Xu X, Hoppman NL, Ketterling RP, Peterson JF, Baughn LB. Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL. Leuk Lymphoma. 2022 Sep; 63: 2243-2246.

                


                  Yang F, Akkari Y, Fan G, Olson S, Moore S. A novel heptasomy 21 associated with complete loss of heterozygosity and loss of function RUNX1 mutation in acute myeloid leukemia. Cancer Genet. 2022 Aug; 266-267: 69-73.

                


                  Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul; 36: 1703-1719.

                


                  Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 May; 24: 986-998.

                


                  Arcila ME, Snow AN, Akkari YMN, Chabot-Richards D, Pancholi P, Tafe LJ. Molecular Pathology Education: A Suggested Framework for Primary Care Resident Training in Genomic Medicine: A Report of the Association for Molecular Pathology Training and Education Committee. J Mol Diagn. 2022 May; 24: 430-441.

                


                  Akkari YMN, Baughn LB, Dubuc AM, Smith AC, Mallo M, Dal Cin P, Diez Campelo M, Gallego MS, Granada Font I, Haase DT, Schlegelberger B, Slavutsky I, Mecucci C, Levine RL, Hasserjian RP, Solé F, Levy B, Xu X. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood. 2022 Apr 14; 139: 2273-2284.

                


                  Wagner AH, Akkari Y, Li M, Roy A, Tsuchiya K, Raca G. Recommendations for future extensions to the HGNC gene fusion nomenclature. Leukemia. 2021 Dec; 35: 3611-3612.

                


                  Shao L, Akkari Y, Cooley LD, Miller DT, Seifert BA, Wolff DJ, Mikhail FM, ACMG Laboratory Quality Assurance Committee. Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021 Oct; 23: 1818-1829.

                


                  Larson DP, Akkari YM, Van Dyke DL, Raca G, Gardner JA, Rehder CW, Kaiser-Rogers KA, Eagle P, Yuhas JA, Gu J, Toydemir RM, Kearney H, Conlin LK, Tang G, Dolan MM, Ketterling RP, Peterson JF. Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee. Arch Pathol Lab Med. 2021 Feb 1; 145: 176-190.

                


                  Akkari YMN, Bruyere H, Hagelstrom RT, Kanagal-Shamanna R, Liu J, Luo M, Mikhail FM, Pitel BA, Raca G, Shago M, Shao L, Smith LR, Smolarek TA, Yenamandra A, Baughn LB. Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia. Cancer Genet. 2020 May; 243: 52-72.

                


                  Punj S, Akkari Y, Huang J, Yang F, Creason A, Pak C, Potter A, Dorschner MO, Nickerson DA, Robertson PD, Jarvik GP, Amendola LM, Schleit J, Simpson DK, Rope AF, Reiss J, Kauffman T, Gilmore MJ, Himes P, Wilfond B, Goddard KAB, Richards CS. Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory. Am J Hum Genet. 2018 Jun 7; 102: 1078-1089.

View More Publications

Education

Date of Appointment at Nationwide Children’s Hospital: 07/11/2022

Graduate School

The Ohio State University

Date Completed: 03/01/1997

Undergraduate School

American University of Beirut

Date Completed: 12/01/1989

Professional Experience

2022 - Present Nationwide Children’s Hospital, Senior Director, Institute for Genomic Medicine2007 - 2022 Legacy Health, Scientific Director, Cytogenetics and Molecular Pathology

Contact Information

Institute for Genomic Medicine

Call us at: (614) 722-2859

                    575 Children’s CrossroadColumbus, OH 43215 (map)

Connect with Yassmine MN Akkari

Connect on Twitter

Contact Information

Call us at: (614) 722-2859

Institute for Genomic Medicine575 Children’s CrossroadColumbus, OH 43215 (map)

Learn more about Yassmine MN Akkari

Contact Information

  • Call us at:
  • (614) 722-2859
  • Institute for Genomic Medicine575 Children’s CrossroadColumbus, OH 43215 (map)

Learn more about Yassmine MN Akkari

Biography

Yassmine Akkari, PhD, is a senior director within the Institute for Genomic Medicine at Nationwide Children’s Hospital. She is triple certified by the American Board of Medical Genetics and Genomics in the specialties of Clinical Cytogenetics, Clinical Molecular Genetics and PhD Medical Genetics. She earned her Bachelor of Sciences degree in Biology from the American University of Beirut and her PhD in Molecular Genetics at The Ohio State University. Following her postdoctoral research and clinical training at the Oregon Health & Sciences University (OHSU), she joined Legacy Health (LH) in Portland, Oregon as the Scientific director of Cytogenetics and Molecular Pathology. During her tenure at LH, she contributed to the successful validation of cytogenetic testing for both germline and somatic specimens, pan-cancer solid tumor next generation sequencing gene panels, and infectious disease, and directed all aspects of clinical genetics operations and workflow. In addition, she provided genetic counseling services for patients with complex genomic results in both the pediatric and prenatal clinics. She also participated in the successful accreditation of the Cytogenetics and Molecular Pathology laboratories at LH to the ISO 15189 standard focusing on the continuum of care directly connected with improved patient safety, risk mitigation and operational efficiency. Dr. Akkari has served as the President of the Cancer Genomics Consortium (CGC), the Vice Chair of the CAP/ACMG Cytogenetics resource Committee, and the Chair of the Association of Molecular Pathology (AMP) Training and Education Committee. Currently, she is an Expert Member of the WHO Blue Books for hematopoietic and lymphoid tissues and genetic tumor syndromes, the Chair-elect of AMP’s Program Committee, and is a member of the Children’s Oncology Group Cytogenetics Committee and the ACMG Laboratory Quality Assurance Committee. She is interested in all aspects of genomics as it pertains to disease diagnostics and therapy. This includes test development and clinical validations particularly in the setting of pediatric hematologic disease, CNS tumors and genetic predisposition syndromes.

Biography

Yassmine Akkari, PhD, is a senior director within the Institute for Genomic Medicine at Nationwide Children’s Hospital. She is triple certified by the American Board of Medical Genetics and Genomics in the specialties of Clinical Cytogenetics, Clinical Molecular Genetics and PhD Medical Genetics. She earned her Bachelor of Sciences degree in Biology from the American University of Beirut and her PhD in Molecular Genetics at The Ohio State University. Following her postdoctoral research and clinical training at the Oregon Health & Sciences University (OHSU), she joined Legacy Health (LH) in Portland, Oregon as the Scientific director of Cytogenetics and Molecular Pathology. During her tenure at LH, she contributed to the successful validation of cytogenetic testing for both germline and somatic specimens, pan-cancer solid tumor next generation sequencing gene panels, and infectious disease, and directed all aspects of clinical genetics operations and workflow. In addition, she provided genetic counseling services for patients with complex genomic results in both the pediatric and prenatal clinics. She also participated in the successful accreditation of the Cytogenetics and Molecular Pathology laboratories at LH to the ISO 15189 standard focusing on the continuum of care directly connected with improved patient safety, risk mitigation and operational efficiency. Dr. Akkari has served as the President of the Cancer Genomics Consortium (CGC), the Vice Chair of the CAP/ACMG Cytogenetics resource Committee, and the Chair of the Association of Molecular Pathology (AMP) Training and Education Committee. Currently, she is an Expert Member of the WHO Blue Books for hematopoietic and lymphoid tissues and genetic tumor syndromes, the Chair-elect of AMP’s Program Committee, and is a member of the Children’s Oncology Group Cytogenetics Committee and the ACMG Laboratory Quality Assurance Committee. She is interested in all aspects of genomics as it pertains to disease diagnostics and therapy. This includes test development and clinical validations particularly in the setting of pediatric hematologic disease, CNS tumors and genetic predisposition syndromes.

Biography

Yassmine Akkari, PhD, is a senior director within the Institute for Genomic Medicine at Nationwide Children’s Hospital. She is triple certified by the American Board of Medical Genetics and Genomics in the specialties of Clinical Cytogenetics, Clinical Molecular Genetics and PhD Medical Genetics. She earned her Bachelor of Sciences degree in Biology from the American University of Beirut and her PhD in Molecular Genetics at The Ohio State University. Following her postdoctoral research and clinical training at the Oregon Health & Sciences University (OHSU), she joined Legacy Health (LH) in Portland, Oregon as the Scientific director of Cytogenetics and Molecular Pathology. During her tenure at LH, she contributed to the successful validation of cytogenetic testing for both germline and somatic specimens, pan-cancer solid tumor next generation sequencing gene panels, and infectious disease, and directed all aspects of clinical genetics operations and workflow. In addition, she provided genetic counseling services for patients with complex genomic results in both the pediatric and prenatal clinics. She also participated in the successful accreditation of the Cytogenetics and Molecular Pathology laboratories at LH to the ISO 15189 standard focusing on the continuum of care directly connected with improved patient safety, risk mitigation and operational efficiency. Dr. Akkari has served as the President of the Cancer Genomics Consortium (CGC), the Vice Chair of the CAP/ACMG Cytogenetics resource Committee, and the Chair of the Association of Molecular Pathology (AMP) Training and Education Committee. Currently, she is an Expert Member of the WHO Blue Books for hematopoietic and lymphoid tissues and genetic tumor syndromes, the Chair-elect of AMP’s Program Committee, and is a member of the Children’s Oncology Group Cytogenetics Committee and the ACMG Laboratory Quality Assurance Committee. She is interested in all aspects of genomics as it pertains to disease diagnostics and therapy. This includes test development and clinical validations particularly in the setting of pediatric hematologic disease, CNS tumors and genetic predisposition syndromes.

Yassmine Akkari, PhD, is a senior director within the Institute for Genomic Medicine at Nationwide Children’s Hospital. She is triple certified by the American Board of Medical Genetics and Genomics in the specialties of Clinical Cytogenetics, Clinical Molecular Genetics and PhD Medical Genetics. She earned her Bachelor of Sciences degree in Biology from the American University of Beirut and her PhD in Molecular Genetics at The Ohio State University. Following her postdoctoral research and clinical training at the Oregon Health & Sciences University (OHSU), she joined Legacy Health (LH) in Portland, Oregon as the Scientific director of Cytogenetics and Molecular Pathology. During her tenure at LH, she contributed to the successful validation of cytogenetic testing for both germline and somatic specimens, pan-cancer solid tumor next generation sequencing gene panels, and infectious disease, and directed all aspects of clinical genetics operations and workflow. In addition, she provided genetic counseling services for patients with complex genomic results in both the pediatric and prenatal clinics. She also participated in the successful accreditation of the Cytogenetics and Molecular Pathology laboratories at LH to the ISO 15189 standard focusing on the continuum of care directly connected with improved patient safety, risk mitigation and operational efficiency. Dr. Akkari has served as the President of the Cancer Genomics Consortium (CGC), the Vice Chair of the CAP/ACMG Cytogenetics resource Committee, and the Chair of the Association of Molecular Pathology (AMP) Training and Education Committee. Currently, she is an Expert Member of the WHO Blue Books for hematopoietic and lymphoid tissues and genetic tumor syndromes, the Chair-elect of AMP’s Program Committee, and is a member of the Children’s Oncology Group Cytogenetics Committee and the ACMG Laboratory Quality Assurance Committee. She is interested in all aspects of genomics as it pertains to disease diagnostics and therapy. This includes test development and clinical validations particularly in the setting of pediatric hematologic disease, CNS tumors and genetic predisposition syndromes.

Yassmine Akkari, PhD, is a senior director within the Institute for Genomic Medicine at Nationwide Children’s Hospital. She is triple certified by the American Board of Medical Genetics and Genomics in the specialties of Clinical Cytogenetics, Clinical Molecular Genetics and PhD Medical Genetics. She earned her Bachelor of Sciences degree in Biology from the American University of Beirut and her PhD in Molecular Genetics at The Ohio State University. Following her postdoctoral research and clinical training at the Oregon Health & Sciences University (OHSU), she joined Legacy Health (LH) in Portland, Oregon as the Scientific director of Cytogenetics and Molecular Pathology. During her tenure at LH, she contributed to the successful validation of cytogenetic testing for both germline and somatic specimens, pan-cancer solid tumor next generation sequencing gene panels, and infectious disease, and directed all aspects of clinical genetics operations and workflow. In addition, she provided genetic counseling services for patients with complex genomic results in both the pediatric and prenatal clinics. She also participated in the successful accreditation of the Cytogenetics and Molecular Pathology laboratories at LH to the ISO 15189 standard focusing on the continuum of care directly connected with improved patient safety, risk mitigation and operational efficiency.

Dr. Akkari has served as the President of the Cancer Genomics Consortium (CGC), the Vice Chair of the CAP/ACMG Cytogenetics resource Committee, and the Chair of the Association of Molecular Pathology (AMP) Training and Education Committee. Currently, she is an Expert Member of the WHO Blue Books for hematopoietic and lymphoid tissues and genetic tumor syndromes, the Chair-elect of AMP’s Program Committee, and is a member of the Children’s Oncology Group Cytogenetics Committee and the ACMG Laboratory Quality Assurance Committee.

She is interested in all aspects of genomics as it pertains to disease diagnostics and therapy. This includes test development and clinical validations particularly in the setting of pediatric hematologic disease, CNS tumors and genetic predisposition syndromes.

Awards, Honors & Organizations

Expert Member for Genetic Tumor Syndromes, WHO-IARC, 2022 - Present Expert Member for Hematologic Malignancies, WHO-IARC, 2021 - Present Member, ClinGen Pediatric Cancer Taskforce, 2021 - Present Editorial Board, Head and Neck Pathology, 2021 - Present Board of Directors, Program Chair-Elect, Association for Molecular Pathologists, 2021 - 2023 Member, ACMG Laboratory Quality Assurance Committee, 2020 - Present Past-President, Cancer Genomics Consortium (CGC), 2020 - 2021 Vice Chair, CAP/ACMG Training and Education Committee, 2019 - 2021 Member, Children’s Oncology Group (COG) Cytogenetics Steering Committee, 2018 - Present Editorial Advisor, Medical Lab Management, 2018 - Present Vice Chair, CAP/ACMG Cytogenetics Committee, 2018 - 2021 Member, CAP/ACMG Cytogenetics Committee, 2013 - 2018 Fellow, American College of Medical Genetics and Genomics, 2005 - Present

Awards, Honors & Organizations

Expert Member for Genetic Tumor Syndromes, WHO-IARC, 2022 - Present Expert Member for Hematologic Malignancies, WHO-IARC, 2021 - Present Member, ClinGen Pediatric Cancer Taskforce, 2021 - Present Editorial Board, Head and Neck Pathology, 2021 - Present Board of Directors, Program Chair-Elect, Association for Molecular Pathologists, 2021 - 2023 Member, ACMG Laboratory Quality Assurance Committee, 2020 - Present Past-President, Cancer Genomics Consortium (CGC), 2020 - 2021 Vice Chair, CAP/ACMG Training and Education Committee, 2019 - 2021 Member, Children’s Oncology Group (COG) Cytogenetics Steering Committee, 2018 - Present Editorial Advisor, Medical Lab Management, 2018 - Present Vice Chair, CAP/ACMG Cytogenetics Committee, 2018 - 2021 Member, CAP/ACMG Cytogenetics Committee, 2013 - 2018 Fellow, American College of Medical Genetics and Genomics, 2005 - Present

Awards, Honors & Organizations

Expert Member for Genetic Tumor Syndromes, WHO-IARC, 2022 - Present Expert Member for Hematologic Malignancies, WHO-IARC, 2021 - Present Member, ClinGen Pediatric Cancer Taskforce, 2021 - Present Editorial Board, Head and Neck Pathology, 2021 - Present Board of Directors, Program Chair-Elect, Association for Molecular Pathologists, 2021 - 2023 Member, ACMG Laboratory Quality Assurance Committee, 2020 - Present Past-President, Cancer Genomics Consortium (CGC), 2020 - 2021 Vice Chair, CAP/ACMG Training and Education Committee, 2019 - 2021 Member, Children’s Oncology Group (COG) Cytogenetics Steering Committee, 2018 - Present Editorial Advisor, Medical Lab Management, 2018 - Present Vice Chair, CAP/ACMG Cytogenetics Committee, 2018 - 2021 Member, CAP/ACMG Cytogenetics Committee, 2013 - 2018 Fellow, American College of Medical Genetics and Genomics, 2005 - Present

Expert Member for Genetic Tumor Syndromes, WHO-IARC, 2022 - Present Expert Member for Hematologic Malignancies, WHO-IARC, 2021 - Present Member, ClinGen Pediatric Cancer Taskforce, 2021 - Present Editorial Board, Head and Neck Pathology, 2021 - Present Board of Directors, Program Chair-Elect, Association for Molecular Pathologists, 2021 - 2023 Member, ACMG Laboratory Quality Assurance Committee, 2020 - Present Past-President, Cancer Genomics Consortium (CGC), 2020 - 2021 Vice Chair, CAP/ACMG Training and Education Committee, 2019 - 2021 Member, Children’s Oncology Group (COG) Cytogenetics Steering Committee, 2018 - Present Editorial Advisor, Medical Lab Management, 2018 - Present Vice Chair, CAP/ACMG Cytogenetics Committee, 2018 - 2021 Member, CAP/ACMG Cytogenetics Committee, 2013 - 2018 Fellow, American College of Medical Genetics and Genomics, 2005 - Present

  • Expert Member for Genetic Tumor Syndromes, WHO-IARC, 2022 - Present
  • Expert Member for Hematologic Malignancies, WHO-IARC, 2021 - Present
  • Member, ClinGen Pediatric Cancer Taskforce, 2021 - Present
  • Editorial Board, Head and Neck Pathology, 2021 - Present
  • Board of Directors, Program Chair-Elect, Association for Molecular Pathologists, 2021 - 2023
  • Member, ACMG Laboratory Quality Assurance Committee, 2020 - Present
  • Past-President, Cancer Genomics Consortium (CGC), 2020 - 2021
  • Vice Chair, CAP/ACMG Training and Education Committee, 2019 - 2021
  • Member, Children’s Oncology Group (COG) Cytogenetics Steering Committee, 2018 - Present
  • Editorial Advisor, Medical Lab Management, 2018 - Present
  • Vice Chair, CAP/ACMG Cytogenetics Committee, 2018 - 2021
  • Member, CAP/ACMG Cytogenetics Committee, 2013 - 2018
  • Fellow, American College of Medical Genetics and Genomics, 2005 - Present

Research

Publications

                  Koleilat A, Smadbeck JB, Zepeda-Mendoza CJ, Williamson CM, Pitel BA, Golden CL, Xu X, Greipp PT, Ketterling RP, Hoppman NL, Peterson JF, Harrison CJ, Akkari YMN, Tsuchiya KD, Shago M, Baughn LB. Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children's Oncology Group. Genes Chromosomes Cancer. 2022 Dec; 61: 710-719.

                


                  Dungan JS, Klugman S, Darilek S, Malinowski J, Akkari YMN, Monaghan KG, Erwin A, Best RG, ACMG Board of Directors. Electronic address: documents@acmg.net. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2022 Dec 13;  

                


                  Levy B, Baughn LB, Akkari YMN, Chartrand S, LaBarge B, Claxton DF, Lennon PA, Cujar C, Kolhe R, Kroeger K, Pitel B, Sahajpal N, Sathanoori M, Vlad G, Zhang L, Fang M, Kanagal-Shamanna R, Broach JR. Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation. Blood Adv. 2022 Nov 23;  

                


                  Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 Sep; 24: 1991.

                


                  Gagnon MF, Smadbeck JB, Sharma N, Blackburn PR, Demasi Benevides J, Akkari YMN, Jaroscak JJ, Znoyko I, Wolff DJ, Schandl CA, Meyer R, Greipp PT, Xu X, Hoppman NL, Ketterling RP, Peterson JF, Baughn LB. Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL. Leuk Lymphoma. 2022 Sep; 63: 2243-2246.

                


                  Yang F, Akkari Y, Fan G, Olson S, Moore S. A novel heptasomy 21 associated with complete loss of heterozygosity and loss of function RUNX1 mutation in acute myeloid leukemia. Cancer Genet. 2022 Aug; 266-267: 69-73.

                


                  Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul; 36: 1703-1719.

                


                  Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 May; 24: 986-998.

                


                  Arcila ME, Snow AN, Akkari YMN, Chabot-Richards D, Pancholi P, Tafe LJ. Molecular Pathology Education: A Suggested Framework for Primary Care Resident Training in Genomic Medicine: A Report of the Association for Molecular Pathology Training and Education Committee. J Mol Diagn. 2022 May; 24: 430-441.

                


                  Akkari YMN, Baughn LB, Dubuc AM, Smith AC, Mallo M, Dal Cin P, Diez Campelo M, Gallego MS, Granada Font I, Haase DT, Schlegelberger B, Slavutsky I, Mecucci C, Levine RL, Hasserjian RP, Solé F, Levy B, Xu X. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood. 2022 Apr 14; 139: 2273-2284.

                


                  Wagner AH, Akkari Y, Li M, Roy A, Tsuchiya K, Raca G. Recommendations for future extensions to the HGNC gene fusion nomenclature. Leukemia. 2021 Dec; 35: 3611-3612.

                


                  Shao L, Akkari Y, Cooley LD, Miller DT, Seifert BA, Wolff DJ, Mikhail FM, ACMG Laboratory Quality Assurance Committee. Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021 Oct; 23: 1818-1829.

                


                  Larson DP, Akkari YM, Van Dyke DL, Raca G, Gardner JA, Rehder CW, Kaiser-Rogers KA, Eagle P, Yuhas JA, Gu J, Toydemir RM, Kearney H, Conlin LK, Tang G, Dolan MM, Ketterling RP, Peterson JF. Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee. Arch Pathol Lab Med. 2021 Feb 1; 145: 176-190.

                


                  Akkari YMN, Bruyere H, Hagelstrom RT, Kanagal-Shamanna R, Liu J, Luo M, Mikhail FM, Pitel BA, Raca G, Shago M, Shao L, Smith LR, Smolarek TA, Yenamandra A, Baughn LB. Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia. Cancer Genet. 2020 May; 243: 52-72.

                


                  Punj S, Akkari Y, Huang J, Yang F, Creason A, Pak C, Potter A, Dorschner MO, Nickerson DA, Robertson PD, Jarvik GP, Amendola LM, Schleit J, Simpson DK, Rope AF, Reiss J, Kauffman T, Gilmore MJ, Himes P, Wilfond B, Goddard KAB, Richards CS. Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory. Am J Hum Genet. 2018 Jun 7; 102: 1078-1089.

View More Publications

Research

Publications

                  Koleilat A, Smadbeck JB, Zepeda-Mendoza CJ, Williamson CM, Pitel BA, Golden CL, Xu X, Greipp PT, Ketterling RP, Hoppman NL, Peterson JF, Harrison CJ, Akkari YMN, Tsuchiya KD, Shago M, Baughn LB. Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children's Oncology Group. Genes Chromosomes Cancer. 2022 Dec; 61: 710-719.

                


                  Dungan JS, Klugman S, Darilek S, Malinowski J, Akkari YMN, Monaghan KG, Erwin A, Best RG, ACMG Board of Directors. Electronic address: documents@acmg.net. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2022 Dec 13;  

                


                  Levy B, Baughn LB, Akkari YMN, Chartrand S, LaBarge B, Claxton DF, Lennon PA, Cujar C, Kolhe R, Kroeger K, Pitel B, Sahajpal N, Sathanoori M, Vlad G, Zhang L, Fang M, Kanagal-Shamanna R, Broach JR. Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation. Blood Adv. 2022 Nov 23;  

                


                  Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 Sep; 24: 1991.

                


                  Gagnon MF, Smadbeck JB, Sharma N, Blackburn PR, Demasi Benevides J, Akkari YMN, Jaroscak JJ, Znoyko I, Wolff DJ, Schandl CA, Meyer R, Greipp PT, Xu X, Hoppman NL, Ketterling RP, Peterson JF, Baughn LB. Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL. Leuk Lymphoma. 2022 Sep; 63: 2243-2246.

                


                  Yang F, Akkari Y, Fan G, Olson S, Moore S. A novel heptasomy 21 associated with complete loss of heterozygosity and loss of function RUNX1 mutation in acute myeloid leukemia. Cancer Genet. 2022 Aug; 266-267: 69-73.

                


                  Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul; 36: 1703-1719.

                


                  Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 May; 24: 986-998.

                


                  Arcila ME, Snow AN, Akkari YMN, Chabot-Richards D, Pancholi P, Tafe LJ. Molecular Pathology Education: A Suggested Framework for Primary Care Resident Training in Genomic Medicine: A Report of the Association for Molecular Pathology Training and Education Committee. J Mol Diagn. 2022 May; 24: 430-441.

                


                  Akkari YMN, Baughn LB, Dubuc AM, Smith AC, Mallo M, Dal Cin P, Diez Campelo M, Gallego MS, Granada Font I, Haase DT, Schlegelberger B, Slavutsky I, Mecucci C, Levine RL, Hasserjian RP, Solé F, Levy B, Xu X. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood. 2022 Apr 14; 139: 2273-2284.

                


                  Wagner AH, Akkari Y, Li M, Roy A, Tsuchiya K, Raca G. Recommendations for future extensions to the HGNC gene fusion nomenclature. Leukemia. 2021 Dec; 35: 3611-3612.

                


                  Shao L, Akkari Y, Cooley LD, Miller DT, Seifert BA, Wolff DJ, Mikhail FM, ACMG Laboratory Quality Assurance Committee. Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021 Oct; 23: 1818-1829.

                


                  Larson DP, Akkari YM, Van Dyke DL, Raca G, Gardner JA, Rehder CW, Kaiser-Rogers KA, Eagle P, Yuhas JA, Gu J, Toydemir RM, Kearney H, Conlin LK, Tang G, Dolan MM, Ketterling RP, Peterson JF. Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee. Arch Pathol Lab Med. 2021 Feb 1; 145: 176-190.

                


                  Akkari YMN, Bruyere H, Hagelstrom RT, Kanagal-Shamanna R, Liu J, Luo M, Mikhail FM, Pitel BA, Raca G, Shago M, Shao L, Smith LR, Smolarek TA, Yenamandra A, Baughn LB. Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia. Cancer Genet. 2020 May; 243: 52-72.

                


                  Punj S, Akkari Y, Huang J, Yang F, Creason A, Pak C, Potter A, Dorschner MO, Nickerson DA, Robertson PD, Jarvik GP, Amendola LM, Schleit J, Simpson DK, Rope AF, Reiss J, Kauffman T, Gilmore MJ, Himes P, Wilfond B, Goddard KAB, Richards CS. Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory. Am J Hum Genet. 2018 Jun 7; 102: 1078-1089.

View More Publications

Research

Publications

                  Koleilat A, Smadbeck JB, Zepeda-Mendoza CJ, Williamson CM, Pitel BA, Golden CL, Xu X, Greipp PT, Ketterling RP, Hoppman NL, Peterson JF, Harrison CJ, Akkari YMN, Tsuchiya KD, Shago M, Baughn LB. Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children's Oncology Group. Genes Chromosomes Cancer. 2022 Dec; 61: 710-719.

                


                  Dungan JS, Klugman S, Darilek S, Malinowski J, Akkari YMN, Monaghan KG, Erwin A, Best RG, ACMG Board of Directors. Electronic address: documents@acmg.net. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2022 Dec 13;  

                


                  Levy B, Baughn LB, Akkari YMN, Chartrand S, LaBarge B, Claxton DF, Lennon PA, Cujar C, Kolhe R, Kroeger K, Pitel B, Sahajpal N, Sathanoori M, Vlad G, Zhang L, Fang M, Kanagal-Shamanna R, Broach JR. Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation. Blood Adv. 2022 Nov 23;  

                


                  Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 Sep; 24: 1991.

                


                  Gagnon MF, Smadbeck JB, Sharma N, Blackburn PR, Demasi Benevides J, Akkari YMN, Jaroscak JJ, Znoyko I, Wolff DJ, Schandl CA, Meyer R, Greipp PT, Xu X, Hoppman NL, Ketterling RP, Peterson JF, Baughn LB. Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL. Leuk Lymphoma. 2022 Sep; 63: 2243-2246.

                


                  Yang F, Akkari Y, Fan G, Olson S, Moore S. A novel heptasomy 21 associated with complete loss of heterozygosity and loss of function RUNX1 mutation in acute myeloid leukemia. Cancer Genet. 2022 Aug; 266-267: 69-73.

                


                  Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul; 36: 1703-1719.

                


                  Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 May; 24: 986-998.

                


                  Arcila ME, Snow AN, Akkari YMN, Chabot-Richards D, Pancholi P, Tafe LJ. Molecular Pathology Education: A Suggested Framework for Primary Care Resident Training in Genomic Medicine: A Report of the Association for Molecular Pathology Training and Education Committee. J Mol Diagn. 2022 May; 24: 430-441.

                


                  Akkari YMN, Baughn LB, Dubuc AM, Smith AC, Mallo M, Dal Cin P, Diez Campelo M, Gallego MS, Granada Font I, Haase DT, Schlegelberger B, Slavutsky I, Mecucci C, Levine RL, Hasserjian RP, Solé F, Levy B, Xu X. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood. 2022 Apr 14; 139: 2273-2284.

                


                  Wagner AH, Akkari Y, Li M, Roy A, Tsuchiya K, Raca G. Recommendations for future extensions to the HGNC gene fusion nomenclature. Leukemia. 2021 Dec; 35: 3611-3612.

                


                  Shao L, Akkari Y, Cooley LD, Miller DT, Seifert BA, Wolff DJ, Mikhail FM, ACMG Laboratory Quality Assurance Committee. Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021 Oct; 23: 1818-1829.

                


                  Larson DP, Akkari YM, Van Dyke DL, Raca G, Gardner JA, Rehder CW, Kaiser-Rogers KA, Eagle P, Yuhas JA, Gu J, Toydemir RM, Kearney H, Conlin LK, Tang G, Dolan MM, Ketterling RP, Peterson JF. Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee. Arch Pathol Lab Med. 2021 Feb 1; 145: 176-190.

                


                  Akkari YMN, Bruyere H, Hagelstrom RT, Kanagal-Shamanna R, Liu J, Luo M, Mikhail FM, Pitel BA, Raca G, Shago M, Shao L, Smith LR, Smolarek TA, Yenamandra A, Baughn LB. Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia. Cancer Genet. 2020 May; 243: 52-72.

                


                  Punj S, Akkari Y, Huang J, Yang F, Creason A, Pak C, Potter A, Dorschner MO, Nickerson DA, Robertson PD, Jarvik GP, Amendola LM, Schleit J, Simpson DK, Rope AF, Reiss J, Kauffman T, Gilmore MJ, Himes P, Wilfond B, Goddard KAB, Richards CS. Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory. Am J Hum Genet. 2018 Jun 7; 102: 1078-1089.

View More Publications

Publications

                  Koleilat A, Smadbeck JB, Zepeda-Mendoza CJ, Williamson CM, Pitel BA, Golden CL, Xu X, Greipp PT, Ketterling RP, Hoppman NL, Peterson JF, Harrison CJ, Akkari YMN, Tsuchiya KD, Shago M, Baughn LB. Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children's Oncology Group. Genes Chromosomes Cancer. 2022 Dec; 61: 710-719.

                


                  Dungan JS, Klugman S, Darilek S, Malinowski J, Akkari YMN, Monaghan KG, Erwin A, Best RG, ACMG Board of Directors. Electronic address: documents@acmg.net. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2022 Dec 13;  

                


                  Levy B, Baughn LB, Akkari YMN, Chartrand S, LaBarge B, Claxton DF, Lennon PA, Cujar C, Kolhe R, Kroeger K, Pitel B, Sahajpal N, Sathanoori M, Vlad G, Zhang L, Fang M, Kanagal-Shamanna R, Broach JR. Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation. Blood Adv. 2022 Nov 23;  

                


                  Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 Sep; 24: 1991.

                


                  Gagnon MF, Smadbeck JB, Sharma N, Blackburn PR, Demasi Benevides J, Akkari YMN, Jaroscak JJ, Znoyko I, Wolff DJ, Schandl CA, Meyer R, Greipp PT, Xu X, Hoppman NL, Ketterling RP, Peterson JF, Baughn LB. Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL. Leuk Lymphoma. 2022 Sep; 63: 2243-2246.

                


                  Yang F, Akkari Y, Fan G, Olson S, Moore S. A novel heptasomy 21 associated with complete loss of heterozygosity and loss of function RUNX1 mutation in acute myeloid leukemia. Cancer Genet. 2022 Aug; 266-267: 69-73.

                


                  Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul; 36: 1703-1719.

                


                  Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 May; 24: 986-998.

                


                  Arcila ME, Snow AN, Akkari YMN, Chabot-Richards D, Pancholi P, Tafe LJ. Molecular Pathology Education: A Suggested Framework for Primary Care Resident Training in Genomic Medicine: A Report of the Association for Molecular Pathology Training and Education Committee. J Mol Diagn. 2022 May; 24: 430-441.

                


                  Akkari YMN, Baughn LB, Dubuc AM, Smith AC, Mallo M, Dal Cin P, Diez Campelo M, Gallego MS, Granada Font I, Haase DT, Schlegelberger B, Slavutsky I, Mecucci C, Levine RL, Hasserjian RP, Solé F, Levy B, Xu X. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood. 2022 Apr 14; 139: 2273-2284.

                


                  Wagner AH, Akkari Y, Li M, Roy A, Tsuchiya K, Raca G. Recommendations for future extensions to the HGNC gene fusion nomenclature. Leukemia. 2021 Dec; 35: 3611-3612.

                


                  Shao L, Akkari Y, Cooley LD, Miller DT, Seifert BA, Wolff DJ, Mikhail FM, ACMG Laboratory Quality Assurance Committee. Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021 Oct; 23: 1818-1829.

                


                  Larson DP, Akkari YM, Van Dyke DL, Raca G, Gardner JA, Rehder CW, Kaiser-Rogers KA, Eagle P, Yuhas JA, Gu J, Toydemir RM, Kearney H, Conlin LK, Tang G, Dolan MM, Ketterling RP, Peterson JF. Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee. Arch Pathol Lab Med. 2021 Feb 1; 145: 176-190.

                


                  Akkari YMN, Bruyere H, Hagelstrom RT, Kanagal-Shamanna R, Liu J, Luo M, Mikhail FM, Pitel BA, Raca G, Shago M, Shao L, Smith LR, Smolarek TA, Yenamandra A, Baughn LB. Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia. Cancer Genet. 2020 May; 243: 52-72.

                


                  Punj S, Akkari Y, Huang J, Yang F, Creason A, Pak C, Potter A, Dorschner MO, Nickerson DA, Robertson PD, Jarvik GP, Amendola LM, Schleit J, Simpson DK, Rope AF, Reiss J, Kauffman T, Gilmore MJ, Himes P, Wilfond B, Goddard KAB, Richards CS. Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory. Am J Hum Genet. 2018 Jun 7; 102: 1078-1089.

View More Publications

                  Koleilat A, Smadbeck JB, Zepeda-Mendoza CJ, Williamson CM, Pitel BA, Golden CL, Xu X, Greipp PT, Ketterling RP, Hoppman NL, Peterson JF, Harrison CJ, Akkari YMN, Tsuchiya KD, Shago M, Baughn LB. Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children's Oncology Group. Genes Chromosomes Cancer. 2022 Dec; 61: 710-719.

                


                  Dungan JS, Klugman S, Darilek S, Malinowski J, Akkari YMN, Monaghan KG, Erwin A, Best RG, ACMG Board of Directors. Electronic address: documents@acmg.net. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2022 Dec 13;  

                


                  Levy B, Baughn LB, Akkari YMN, Chartrand S, LaBarge B, Claxton DF, Lennon PA, Cujar C, Kolhe R, Kroeger K, Pitel B, Sahajpal N, Sathanoori M, Vlad G, Zhang L, Fang M, Kanagal-Shamanna R, Broach JR. Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation. Blood Adv. 2022 Nov 23;  

                


                  Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 Sep; 24: 1991.

                


                  Gagnon MF, Smadbeck JB, Sharma N, Blackburn PR, Demasi Benevides J, Akkari YMN, Jaroscak JJ, Znoyko I, Wolff DJ, Schandl CA, Meyer R, Greipp PT, Xu X, Hoppman NL, Ketterling RP, Peterson JF, Baughn LB. Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL. Leuk Lymphoma. 2022 Sep; 63: 2243-2246.

                


                  Yang F, Akkari Y, Fan G, Olson S, Moore S. A novel heptasomy 21 associated with complete loss of heterozygosity and loss of function RUNX1 mutation in acute myeloid leukemia. Cancer Genet. 2022 Aug; 266-267: 69-73.

                


                  Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul; 36: 1703-1719.

                


                  Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 May; 24: 986-998.

                


                  Arcila ME, Snow AN, Akkari YMN, Chabot-Richards D, Pancholi P, Tafe LJ. Molecular Pathology Education: A Suggested Framework for Primary Care Resident Training in Genomic Medicine: A Report of the Association for Molecular Pathology Training and Education Committee. J Mol Diagn. 2022 May; 24: 430-441.

                


                  Akkari YMN, Baughn LB, Dubuc AM, Smith AC, Mallo M, Dal Cin P, Diez Campelo M, Gallego MS, Granada Font I, Haase DT, Schlegelberger B, Slavutsky I, Mecucci C, Levine RL, Hasserjian RP, Solé F, Levy B, Xu X. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood. 2022 Apr 14; 139: 2273-2284.

                


                  Wagner AH, Akkari Y, Li M, Roy A, Tsuchiya K, Raca G. Recommendations for future extensions to the HGNC gene fusion nomenclature. Leukemia. 2021 Dec; 35: 3611-3612.

                


                  Shao L, Akkari Y, Cooley LD, Miller DT, Seifert BA, Wolff DJ, Mikhail FM, ACMG Laboratory Quality Assurance Committee. Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021 Oct; 23: 1818-1829.

                


                  Larson DP, Akkari YM, Van Dyke DL, Raca G, Gardner JA, Rehder CW, Kaiser-Rogers KA, Eagle P, Yuhas JA, Gu J, Toydemir RM, Kearney H, Conlin LK, Tang G, Dolan MM, Ketterling RP, Peterson JF. Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee. Arch Pathol Lab Med. 2021 Feb 1; 145: 176-190.

                


                  Akkari YMN, Bruyere H, Hagelstrom RT, Kanagal-Shamanna R, Liu J, Luo M, Mikhail FM, Pitel BA, Raca G, Shago M, Shao L, Smith LR, Smolarek TA, Yenamandra A, Baughn LB. Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia. Cancer Genet. 2020 May; 243: 52-72.

                


                  Punj S, Akkari Y, Huang J, Yang F, Creason A, Pak C, Potter A, Dorschner MO, Nickerson DA, Robertson PD, Jarvik GP, Amendola LM, Schleit J, Simpson DK, Rope AF, Reiss J, Kauffman T, Gilmore MJ, Himes P, Wilfond B, Goddard KAB, Richards CS. Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory. Am J Hum Genet. 2018 Jun 7; 102: 1078-1089.

View More Publications

  • Koleilat A, Smadbeck JB, Zepeda-Mendoza CJ, Williamson CM, Pitel BA, Golden CL, Xu X, Greipp PT, Ketterling RP, Hoppman NL, Peterson JF, Harrison CJ, Akkari YMN, Tsuchiya KD, Shago M, Baughn LB. Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children’s Oncology Group. Genes Chromosomes Cancer. 2022 Dec; 61: 710-719.
  • Dungan JS, Klugman S, Darilek S, Malinowski J, Akkari YMN, Monaghan KG, Erwin A, Best RG, ACMG Board of Directors. Electronic address: documents@acmg.net. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2022 Dec 13;
  • Levy B, Baughn LB, Akkari YMN, Chartrand S, LaBarge B, Claxton DF, Lennon PA, Cujar C, Kolhe R, Kroeger K, Pitel B, Sahajpal N, Sathanoori M, Vlad G, Zhang L, Fang M, Kanagal-Shamanna R, Broach JR. Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation. Blood Adv. 2022 Nov 23;
  • Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 Sep; 24: 1991.
  • Gagnon MF, Smadbeck JB, Sharma N, Blackburn PR, Demasi Benevides J, Akkari YMN, Jaroscak JJ, Znoyko I, Wolff DJ, Schandl CA, Meyer R, Greipp PT, Xu X, Hoppman NL, Ketterling RP, Peterson JF, Baughn LB. Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL. Leuk Lymphoma. 2022 Sep; 63: 2243-2246.
  • Yang F, Akkari Y, Fan G, Olson S, Moore S. A novel heptasomy 21 associated with complete loss of heterozygosity and loss of function RUNX1 mutation in acute myeloid leukemia. Cancer Genet. 2022 Aug; 266-267: 69-73.
  • Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul; 36: 1703-1719.
  • Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 May; 24: 986-998.
  • Arcila ME, Snow AN, Akkari YMN, Chabot-Richards D, Pancholi P, Tafe LJ. Molecular Pathology Education: A Suggested Framework for Primary Care Resident Training in Genomic Medicine: A Report of the Association for Molecular Pathology Training and Education Committee. J Mol Diagn. 2022 May; 24: 430-441.
  • Akkari YMN, Baughn LB, Dubuc AM, Smith AC, Mallo M, Dal Cin P, Diez Campelo M, Gallego MS, Granada Font I, Haase DT, Schlegelberger B, Slavutsky I, Mecucci C, Levine RL, Hasserjian RP, Solé F, Levy B, Xu X. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood. 2022 Apr 14; 139: 2273-2284.
  • Wagner AH, Akkari Y, Li M, Roy A, Tsuchiya K, Raca G. Recommendations for future extensions to the HGNC gene fusion nomenclature. Leukemia. 2021 Dec; 35: 3611-3612.
  • Shao L, Akkari Y, Cooley LD, Miller DT, Seifert BA, Wolff DJ, Mikhail FM, ACMG Laboratory Quality Assurance Committee. Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021 Oct; 23: 1818-1829.
  • Larson DP, Akkari YM, Van Dyke DL, Raca G, Gardner JA, Rehder CW, Kaiser-Rogers KA, Eagle P, Yuhas JA, Gu J, Toydemir RM, Kearney H, Conlin LK, Tang G, Dolan MM, Ketterling RP, Peterson JF. Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee. Arch Pathol Lab Med. 2021 Feb 1; 145: 176-190.
  • Akkari YMN, Bruyere H, Hagelstrom RT, Kanagal-Shamanna R, Liu J, Luo M, Mikhail FM, Pitel BA, Raca G, Shago M, Shao L, Smith LR, Smolarek TA, Yenamandra A, Baughn LB. Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia. Cancer Genet. 2020 May; 243: 52-72.
  • Punj S, Akkari Y, Huang J, Yang F, Creason A, Pak C, Potter A, Dorschner MO, Nickerson DA, Robertson PD, Jarvik GP, Amendola LM, Schleit J, Simpson DK, Rope AF, Reiss J, Kauffman T, Gilmore MJ, Himes P, Wilfond B, Goddard KAB, Richards CS. Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory. Am J Hum Genet. 2018 Jun 7; 102: 1078-1089.

Education

Date of Appointment at Nationwide Children’s Hospital: 07/11/2022

Graduate School

The Ohio State University

Date Completed: 03/01/1997

Undergraduate School

American University of Beirut

Date Completed: 12/01/1989

Education

Date of Appointment at Nationwide Children’s Hospital: 07/11/2022

Graduate School

The Ohio State University

Date Completed: 03/01/1997

Undergraduate School

American University of Beirut

Date Completed: 12/01/1989

Education

Date of Appointment at Nationwide Children’s Hospital: 07/11/2022

Graduate School

The Ohio State University

Date Completed: 03/01/1997

Undergraduate School

American University of Beirut

Date Completed: 12/01/1989

Date of Appointment at Nationwide Children’s Hospital: 07/11/2022

Graduate School

The Ohio State University

Date Completed: 03/01/1997

Undergraduate School

American University of Beirut

Date Completed: 12/01/1989

Date of Appointment at Nationwide Children’s Hospital: 07/11/2022

Graduate School

The Ohio State University

Date Completed: 03/01/1997

Undergraduate School

American University of Beirut

Date Completed: 12/01/1989

Professional Experience

2022 - Present Nationwide Children’s Hospital, Senior Director, Institute for Genomic Medicine2007 - 2022 Legacy Health, Scientific Director, Cytogenetics and Molecular Pathology

Professional Experience

2022 - Present Nationwide Children’s Hospital, Senior Director, Institute for Genomic Medicine2007 - 2022 Legacy Health, Scientific Director, Cytogenetics and Molecular Pathology

Professional Experience

2022 - Present Nationwide Children’s Hospital, Senior Director, Institute for Genomic Medicine2007 - 2022 Legacy Health, Scientific Director, Cytogenetics and Molecular Pathology

2022 - Present Nationwide Children’s Hospital, Senior Director, Institute for Genomic Medicine2007 - 2022 Legacy Health, Scientific Director, Cytogenetics and Molecular Pathology

2022 - Present Nationwide Children’s Hospital, Senior Director, Institute for Genomic Medicine

Contact Information

Institute for Genomic Medicine

Call us at: (614) 722-2859

                    575 Children’s CrossroadColumbus, OH 43215 (map)

Contact Information

Institute for Genomic Medicine

Call us at: (614) 722-2859

                    575 Children’s CrossroadColumbus, OH 43215 (map)

Contact Information

Institute for Genomic Medicine

Call us at: (614) 722-2859

                    575 Children’s CrossroadColumbus, OH 43215 (map)

Institute for Genomic Medicine

Call us at: (614) 722-2859

                    575 Children’s CrossroadColumbus, OH 43215 (map)

Call us at: (614) 722-2859

                    575 Children’s CrossroadColumbus, OH 43215 (map)

Call us at: (614) 722-2859

                    575 Children’s CrossroadColumbus, OH 43215 (map)
  • Call us at:
  • (614) 722-2859
  • 575 Children’s CrossroadColumbus, OH 43215 (map)

Connect with Yassmine MN Akkari

Connect on Twitter